These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
154 related items for PubMed ID: 3302917
21. Ceftazidime treatment in cystic fibrosis: resistant organisms in sputum and faeces. Dalzell AM, Sunderland D, Hart CA, Heaf DP. Thorax; 1991 Apr; 46(4):239-41. PubMed ID: 1903896 [Abstract] [Full Text] [Related]
22. Chronic Pseudomonas aeruginosa lung infection in cystic fibrosis. A longitudinal study of immune complex activity and inflammatory response in sputum sol-phase of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infections: influence of local steroid treatment. Schiøtz PO, Jørgensen M, Flensborg EW, Faerø O, Husby S, Høiby N, Jacobsen SV, Nielsen H, Svehag SE. Acta Paediatr Scand; 1983 Mar; 72(2):283-7. PubMed ID: 6340415 [Abstract] [Full Text] [Related]
23. Continuous vs thrice-daily ceftazidime for elective intravenous antipseudomonal therapy in cystic fibrosis. Riethmueller J, Junge S, Schroeter TW, Kuemmerer K, Franke P, Ballmann M, Claass A, Broemme S, Jeschke R, Hebestreit A, Staab D, Koetz K, Doering G, Stern M. Infection; 2009 Oct; 37(5):418-23. PubMed ID: 19756419 [Abstract] [Full Text] [Related]
24. Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children. Rappaz I, Decosterd LA, Bille J, Pilet M, Bélaz N, Roulet M. Eur J Pediatr; 2000 Dec; 159(12):919-25. PubMed ID: 11131352 [Abstract] [Full Text] [Related]
25. Management of acute pulmonary exacerbations in cystic fibrosis: a critical appraisal. Nelson JD. J Pediatr; 1985 Jun; 106(6):1030-4. PubMed ID: 3889252 [Abstract] [Full Text] [Related]
26. [Tolerance and efficacy of ceftazidime in combination with aztreonam for exacerbations of cystic fibrosis]. Prévotat A, Leroy S, Perez T, Wallet F, Wallaert B. Rev Mal Respir; 2010 May; 27(5):449-56. PubMed ID: 20569877 [Abstract] [Full Text] [Related]
27. Ceftazidime treatment of chronic Pseudomonas infection in patients with cystic fibrosis. Fluge G, Digranes A, Michalsen H, Stiris T, Bergan T, Qvigstad EK. Eur J Respir Dis; 1987 Oct; 71(4):239-43. PubMed ID: 3319661 [Abstract] [Full Text] [Related]
28. Ceftazidime in treatment of acute pulmonary exacerbations in patients with cystic fibrosis. Padoan R, Brienza A, Crossignani RM, Lodi G, Giunta A, Assael BM, Granata F, Passarella E, Vallaperta PA, Xerri L. J Pediatr; 1983 Aug; 103(2):320-4. PubMed ID: 6348228 [Abstract] [Full Text] [Related]
29. Clinical results and pharmacokinetics of ceftazidime treatment in patients with cystic fibrosis. Strandvik B, Malmborg AS, Alfredson H, Ericsson A. J Antimicrob Chemother; 1983 Jul; 12 Suppl A():283-7. PubMed ID: 6352633 [Abstract] [Full Text] [Related]
30. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. Cantón R, Cobos N, de Gracia J, Baquero F, Honorato J, Gartner S, Alvarez A, Salcedo A, Oliver A, García-Quetglas E, Spanish Consensus Group for Antimicrobial Therapy in the Cystic Fibrosis Patient. Clin Microbiol Infect; 2005 Sep; 11(9):690-703. PubMed ID: 16104983 [Abstract] [Full Text] [Related]
32. Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. Cystic Fibrosis Study Group. Richard DA, Nousia-Arvanitakis S, Sollich V, Hampel BJ, Sommerauer B, Schaad UB. Pediatr Infect Dis J; 1997 Jun; 16(6):572-8. PubMed ID: 9194107 [Abstract] [Full Text] [Related]
36. Antipseudomonal therapy in cystic fibrosis: aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin. Schaad UB, Wedgwood-Krucko J, Guenin K, Buehlmann U, Kraemer R. Eur J Clin Microbiol Infect Dis; 1989 Oct; 8(10):858-65. PubMed ID: 2512129 [Abstract] [Full Text] [Related]
37. Treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis with high or conventional doses of ceftazidime. De Boeck K, Breysem L. J Antimicrob Chemother; 1998 Mar; 41(3):407-9. PubMed ID: 9578170 [Abstract] [Full Text] [Related]
38. Decreased baseline beta-lactamase production and inducibility associated with increased piperacillin susceptibility of Pseudomonas cepacia isolated from children with cystic fibrosis. Chiesa C, Labrozzi PH, Aronoff SC. Pediatr Res; 1986 Nov; 20(11):1174-7. PubMed ID: 3540826 [Abstract] [Full Text] [Related]
39. A comparison of intravitreal piperacillin/tazobactam with ceftazidime in experimental Pseudomonas aeruginosa endophthalmitis. Ozkiriş A, Evereklioglu C, Akgün H, Eşel D, Caner F, Erkiliç K. Exp Eye Res; 2005 Mar; 80(3):361-7. PubMed ID: 15721618 [Abstract] [Full Text] [Related]
40. Correlation between activity of beta-lactam agents in vitro and bacteriological outcome in acute pulmonary exacerbations of cystic fibrosis. Gaillard JL, Cahen P, Delacourt C, Silly C, Le Bourgeois M, Coustère C, de Blic J, Lenoir G, Scheinmann P. Eur J Clin Microbiol Infect Dis; 1995 Apr; 14(4):291-6. PubMed ID: 7649191 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]